Liraglutide

Liraglutide is a GLP-1 receptor agonist used in distinct prescription products. Saxenda has weight-management indications alongside dietary and activity measures. Victoza is labelled for type 2 diabetes and for reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

Both named products use daily injections. An extended duration of action compared with endogenous GLP-1 does not make liraglutide a once-weekly medicine. Product eligibility, dose and follow-up remain separate from the name of the active molecule.

GLP-1 receptor activation affects appetite, gastric emptying and glucose-dependent insulin secretion. The Saxenda label connects weight effects with reduced calorie intake; Victoza’s label describes its glycemic actions. A physiological pathway does not by itself guarantee tolerability or sustained weight loss after stopping treatment.

The outcomes that matter are measured clinical changes. The SCALE trial assessed weight, while LEADER assessed cardiovascular events in a higher-risk diabetes population. They answer different questions.

SCALE enrolled 3,731 adults without type 2 diabetes for 56 weeks. Mean weight loss was 8.4 kg with liraglutide 3 mg daily versus 2.8 kg with placebo, with lifestyle counseling in both groups. The reported analysis used last-observation-carried-forward imputation; a trial mean is not an individual forecast.

At least 5% weight loss occurred in 63.2% versus 27.1%, and more than 10% in 33.1% versus 10.6%. These findings support meaningful weight benefit, without proving that every kilogram lost is fat, muscle is fully preserved or weight will keep falling indefinitely.

The Saxenda adult label starts at 0.6 mg daily and increases by weekly steps to 3 mg daily. It calls for assessing response at week 16 and stopping if less than 4% of baseline weight has been lost. After a gap exceeding three days, its restart instructions return to 0.6 mg rather than resuming a high dose.

Victoza’s adult schedule starts at 0.6 mg daily for one week, then 1.2 mg; 1.8 mg may follow when additional glycemic control is needed. These are different product regimens. A pen is not a single weekly dose, and amounts should not be transferred between products or combined with another liraglutide product.

LEADER randomized 9,340 patients with type 2 diabetes and high cardiovascular risk, with median follow-up of 3.8 years. Major cardiovascular events occurred in 13.0% with liraglutide versus 14.9% with placebo: hazard ratio 0.87 (95% CI 0.78–0.97). This is a favorable clinical outcome, not proof that every person using Saxenda for weight loss has the same risk reduction.

The SCALE weight trial and LEADER differ in population, dose context, endpoint and follow-up. Neither is a direct ranking against newer obesity medicines.

The current Saxenda label includes gastrointestinal effects, pancreatitis, gallbladder disease, dehydration-related kidney injury and aspiration concerns during anesthesia. Its thyroid warning concerns rodent findings with uncertain human relevance; personal/family MTC history, MEN 2 and serious product hypersensitivity are contraindications.

SCALE reported serious events in 6.2% versus 5.0% with placebo. LEADER provides longer clinical follow-up but does not establish freedom from uncommon risks. Sustained benefit and tolerability should be reassessed rather than attributed solely to a natural mechanism.

Liraglutide has useful randomized evidence for weight management and specific diabetes-related outcomes. The weight study does not guarantee a fixed response timeline, permanent weight maintenance after withdrawal or universal lean-mass preservation. LEADER’s longer follow-up should remain attached to its high-risk diabetes population.

The choice of product and ongoing treatment depends on eligibility, response, tolerability and clinical follow-up. Approval of a named medicine does not validate every product sold under the same ingredient name.

Editorial update: October 27, 2026. Current Saxenda and Victoza label sections and original SCALE/LEADER indexed abstracts were checked. Not every full journal paper was obtained. The named-product instructions are not a personalized prescription. This is an editorial source check, not clinician review or a completed whole-family review. Read a key primary source.